Cortexyme, Inc. (CRTX:NASDAQ) Investor Relations Material

Overview

Cortexyme is a biopharmaceutical company that is focused on developing innovative therapies for patients with Alzheimer's disease and other degenerative diseases. The company's lead therapeutic candidate, atuzaginstat (COR388), is currently being studied in an ongoing Phase 2/3 clinical trial for patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific infectious pathogen found in the brain of Alzheimer's patients, which is linked to neurodegeneration and neuroinflammation in animal models. The company's approach represents a promising breakthrough in the treatment of Alzheimer's disease and other neurodegenerative disorders.

Annual Reports

Frequently Asked Questions

What is Cortexyme, Inc.'s ticker?

Cortexyme, Inc.'s ticker is CRTX

What exchange is Cortexyme, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Cortexyme, Inc.'s headquarters?

They are based in South San Francisco, California

How many employees does Cortexyme, Inc. have?

There are 11-50 employees working at Cortexyme, Inc.

What is Cortexyme, Inc.'s website?

It is https://www.cortexyme.com/

What type of sector is Cortexyme, Inc.?

Cortexyme, Inc. is in the Healthcare sector

What type of industry is Cortexyme, Inc.?

Cortexyme, Inc. is in the Biotechnology industry

Who are Cortexyme, Inc.'s peers and competitors?

The following five companies are Cortexyme, Inc.'s industry peers:

- Interpace Biosciences, Inc.

- Acceleron Pharma Inc.

- Cocrystal Pharma, Inc.

- Brickell Biotech, Inc.

- Entasis Therapeutics Holdings Inc.